Bharat Rasayan Limited (BHARATRAS) Fair Value & Analysis
Basic Materials · IN · Market cap ₹21.3B
Fair value as of: Aug 19, 2026
From 23 valuation models · updated yesterday
Share price −2.5% over the past month.
A solid business, but screening 37% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (₹1,134). The favourable scenario is already priced in.
- Solid but not exceptional quality (51/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 19, 2026.
How to read this chart
60‑month range ₹1,209 – ₹3,564 · fair‑value band ₹641.09 – ₹1,134 · the ₹1,280 price screens above the ₹804.63 fair value. Dashed = 300-day average. As of Aug 19, 2026.
Analysis
Bharat Rasayan Limited (BHARATRAS) currently trades at ₹1,280, while our model-based Fair Value estimate is ₹804.63, implying the stock looks roughly 37.1% overvalued today. The Quality Score stands at 51/100 (solid quality), in the Basic Materials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Bharat Rasayan Limited generated revenue of ₹12.3B at a net margin of 10.9%. Revenue declined 12.8% year over year. It earns a return on equity of 11.8%. Net debt stands at ₹298M. Fundamentals as of Aug 19, 2026
Our scenario range runs from ₹641.09 (bear case) to ₹1,134 (bull case); at ₹1,280, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 58% below its 52-week high and 6% above its 52-week low, currently below its 200-day average. For context, the median of 10 Basic Materials peers we cover trades at -13% fair-value upside, at -37%, BHARATRAS screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 23 models by family
Widest divergence: Growth Earnings (₹1,215) versus Asset-Based (₹513.85). Highest evidence: Growth DCF (80).
Notify me when BHARATRAS reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 19, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 52 · Market factors (momentum, volatility) 27
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Bharat Rasayan Limited manufactures and sells technical grade pesticides and intermediates in India. The company offers insecticides, herbicides, fungicides, and intermediates. It also exports its products through multinational agrochemical companies and other traders. Bharat Rasayan Limited was incorporated in 1989 and is based in New Delhi, India.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Bharat Rasayan Limited reported revenue of ₹12.4B in FY2026 versus ₹13.0B in FY2022, a compound −1.2%/yr. Reported net income was ₹1.5B in FY2026, compounding −4.6%/yr from FY2022.
BHARATRAS screens 37% overvalued. Compare with Corteva, Inc →
Peer Group
Agricultural Inputs · 180 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Agricultural Inputs median · lower = cheaper
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Agricultural Inputs stocks, each showing price versus our Fair Value estimate (as of Aug 19, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Corteva, Inc CTVA | $76.22 | $27.81 | -64% |
| Nutrien Ltd NTR | C$93.60 | C$81.69 | -13% |
| Qinghai Salt Lake Industry Co 000792 | ¥27.65 | ¥21.26 | -23% |
| CF Industries Holdings CF | $120.01 | $161.00 | +34% |
| SABIC Agri-Nutrients Company 2020 | 122.90 SAR | 127.31 SAR | +4% |
| Yara International ASA YAR | kr 437.20 | kr 630.39 | +44% |
| Yunnan Yuntianhua Co 600096 | ¥29.82 | ¥42.12 | +41% |
| Asia-potash International Investment (Guangzhou)Co.,Ltd., 000893 | ¥45.86 | ¥38.01 | -17% |
| Coromandel International Limited COROMANDEL | ₹2,039 | ₹817.06 | -60% |
| UPL Limited UPL | ₹568.00 | ₹387.06 | -32% |
Compare Bharat Rasayan Limited with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Basic Materials stocks →
Frequently asked questions
Is Bharat Rasayan Limited (BHARATRAS) overvalued or undervalued?
What is the fair value of BHARATRAS?
What is the quality score of BHARATRAS?
What is the revenue of Bharat Rasayan Limited (BHARATRAS)?
What is the net profit margin of BHARATRAS?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Bharat Rasayan Limited and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.